Category: 936901-72-3

On July 11, 2013, Jin, Meizhong; Petronella, Brenda A.; Cooke, Andy; Kadalbajoo, Mridula; Siu, Kam W.; Kleinberg, Andrew; May, Earl W.; Gokhale, Prafulla C.; Schulz, Ryan; Kahler, Jennifer; Bittner, Mark A.; Foreman, Kenneth; Pachter, Jonathan A.; Wild, Robert; Epstein, David; Mulvihill, Mark J. published an article.Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the article was Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics. And the article contained the following:

This letter describes a series of small mol. inhibitors of IGF-1R with unique time-dependent binding kinetics and slow off-rates. Structure-activity and structure-kinetic relationships were elucidated and guided further optimizations within the series, culminating in compound 2. With an IGF-1R dissociative half-life (t1/2) of >100 h, compound 2 demonstrated significant and extended PD effects in conjunction with tumor growth inhibition in xenograft models at a remarkably low and intermittent dose, which correlated with the observed in vitro slow off-rate properties. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

The Article related to preparation igf1 receptor inhibitor binding kinetics structure, insulin-like growth factor-1 receptor (igf-1r), cancer, slow off-rate, time-dependent inhibition, Pharmacology: Structure-Activity and other aspects.Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On May 17, 2007, Chen, Xin; Coate, Heather; Crew, Andrew Philip; Dong, Han-Qing; Honda, Ayako; Mulvihill, Mark Joseph; Tavares, Paula A.R.; Wang, Jing; Werner, Douglas S.; Mulvihill, Kristen Michelle; Siu, Kam W.; Panicker, Bijoy; Bharadwaj, Apoorba; Arnold, Lee D.; Jin, Meizhong; Volk, Brian; Weng, Qinghua; Beard, James David published a patent.Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the patent was Preparation of substituted imidazopyrazines and related compounds as mTOR inhibitors. And the patent contained the following:

The title compounds I [X1, X2 = N or C(E1)aa; X5 = N, C(E1)aa or N(E1)aa; X3, X4, X6, X7 = N or C, wherein at least one of X3-X7 = N or N(E1)aa; R3 = alkyl, cycloalkyl, aryl, etc.; Q1 = (un)substituted indolyl, benzothiazolyl, etc.; E1 = halo, CF3, OCF3, etc.; aa = 0-1; with provisos] that are inhibitors of mTOR useful in the treatment of cancer, were prepared and formulated. Thus, coupling 8-amino-3-cyclobutyl-1-iodoimidazo[3,4-a]pyrazine with 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole afforded II. The exemplified compounds I showed activity against mTOR kinase as demonstrated in the assays described in this invention. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

The Article related to imidazopyrazine preparation mtor frap protein kinase inhibitor antitumor, imidazotriazine preparation mtor frap protein kinase inhibitor antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Application In Synthesis of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On November 19, 2009, Crew, Andrew P.; Jin, Meizhong; Kadalbajoo, Mridula; Kleinberg, Andrew; Mulvihill, Mark J.; Wang, Jing published a patent.Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the patent was Substituted imidazopyrazines and imidazotriazines as ACK1 inhibitors and their preparation. And the patent contained the following:

The invention relates to fused pyridine-based bicyclic compounds having the structure of formula I, pharmaceutically acceptable salts thereof, preparation, compositions, and disease treatment therewith. Compounds of formula I wherein A is CH and N; Q1 is X1Y1Z1, 1-phenylbenzimidazol-5-yl and carbazolyl; X1 is (un)substituted 5- to 10-membered cyclic ring; Y is CO, O, S, SO, SO2, etc.; Z1 is (un)substituted 5- to 10-membered cyclic ring and C1-6 alkoxy; R1 is SH and derivatives, (un)substituted C1-6 alkyl, (un)substituted 5,6-bicyclic aryl and (un)substituted 3- to 6-membered ring; and pharmaceutically acceptable salt thereof, are claimed. Example compound II was prepared by a general procedure (procedure given). All the invention compounds were evaluated for their ACK1 inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.1759 μM. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

The Article related to imidazopyrazine imidazotriazine preparation ack1 inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Triazines and other aspects.Name: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On March 4, 2021, Rathod, Rajendrasinh Jashvantsinh; Raut, Virendra Narendra; Βhatt, Tushar Bhupendrabhai; Savant, Pratit Viram; Joshi, Kiritkumar Parmeshkumar; Jarag, Tushar Mukund; Chimanwala, Sabbirhusen Yusufbhai; Sengupta, Prabal; Kadiyala, V. S. N. Murty; Chitturi, Trinadha Rao published a patent.SDS of cas: 936901-72-3 The title of the patent was Preparation of cycloalkylidene carboxylic acids and derivatives as BTK inhibitors. And the patent contained the following:

The present invention relates to novel cycloalkylidene carboxylic acids and derivatives thereof of formula I [Ra = N(R2)NR3R4, OH, NR15R16; ring Hy = II-VI; ring A = VII-VIII (wherein R5 = H, halo, OH, etc.; Y1 = CH, N; Y2 = CH and N; Y3 = CH and N; Y4 = N, O and S); W = absent, (CH2)1-2, NH, NHCH2; Y = O, S, NH, etc.; ring B = (un)substituted 6-10 membered aryl, cycloalkyl and 5-10 membered heteroaryl containing 1-3 heteroatoms each independently selected from N, O and S; R1 = H, halo, alkyl, etc.; R2 and R3 = (independently) H, hydroxyalkyl, and alkyl optionally substituted with cycloalkyl; or R2 and R3 together with N atoms to which they are attached form 4-7 membered heterocycloalkyl ring; R4 = C(O)alkyl, C(O)cycloalkyl, C(S)alkyl, etc.; R15 = H or alkyl; R16 = H, OH, alkyl, etc.; m = 1-3; n = 1-3; with the proviso] or pharmaceutically acceptable salts, stereoisomers or deuterated analogs, useful as Bruton tyrosine kinase (BTK) inhibitors. The present disclosure also relates to processes for their preparation, pharmaceutical compositions containing one or more such compounds, and to the use of such compounds and pharmaceutical compositions for the treatment of disorders involving mediation of BTK in humans. E.g., a multi-step synthesis of IX, starting from 3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine, was described. The inhibitory activity of exemplified compounds I was evaluated in the BTK assay employing the ADP-GloTM Platform (data given). The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).SDS of cas: 936901-72-3

The Article related to cycloalkylidene carboxylic acid preparation bruton tyrosine kinase btk inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.SDS of cas: 936901-72-3

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On September 20, 2007, Buck, Elizabeth A.; Griffin, Graeme; Barr, Sharon M. published a patent.Safety of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the patent was Imidazo[1,5-a]pyrazin-8-amine in combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors. And the patent contained the following:

The invention provides a method for manufacturing a medicament intended for treating NSCL, pancreatic, colon or breast cancer tumors or tumor metastases in combination with an EGFR kinase inhibitor, characterized in that an mTOR inhibitor is used, and wherein the inhibitors are intended for administration either simultaneously or sequentially, and with or without administration of addnl. agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also provides a method for manufacturing a medicament intended for treating tumors or tumor metastases in a patient in combination of an EGFR kinase inhibitor, characterized in that an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases is used, and wherein the inhibitors are intended for administration either simultaneously or sequentially, and with or without administration of addnl. agents or treatments, such as other anti-cancer drugs or radiation therapy. The invention also provides a pharmaceutical composition comprising an EGFR kinase inhibitor and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. A preferred example of an EGFR kinase inhibitor that can be used in practicing the methods of this invention is the compound erlotinib HCl (also known as TARCEVA). Example compound I was prepared by cross-coupling of 8-amino-3-cyclobutyl-1-iodoimidazol[3,4-a]pyrazine with 5-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1H-indole. All the invention compounds were evaluated for their EGFR kinase inhibitory activity (some data given). The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Safety of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

The Article related to imidazopyrazinamine preparation egfr kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Safety of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On January 15, 2009, Barr, Sharon; Buck, Elizabeth; Eyzaguirre, Alexandra; Russo, Suzanne; Bhagwat, Shripad published a patent.Electric Literature of 936901-72-3 The title of the patent was Preparation of imidazo[1,5-a]pyrazin-8-amine for use in combination therapy of cancers and cancer metastasis. And the patent contained the following:

The present invention provides a method for treating tumors or tumor metastases in patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of an anti-cancer agents or treatment that elevates pAkt levels in tumor cells and mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. Examples of such anti-cancer agents or treatments include doxorubicin, cisplatin, or ionizing radiation. The invention also provides a method for treating tumors or tumor metastases in a patient, comprising administering to said patient simultaneously or sequentially a therapeutically effective amount of a combination of the anti-cancer agent melphalan or 5-FU, and mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases. The invention also provides a pharmaceutical composition comprising an anti-cancer agent or treatment that elevates pAkt levels in tumor cells and an mTOR inhibitor that binds to and directly inhibits both mTORC1 and mTORC2 kinases, in a pharmaceutically acceptable carrier. Example compound I was prepared by cross-coupling of 8-amino-3-cyclobutyl-1-iodoimidazol[3,4-a]pyrazine with 5-(4,4,5,5-tetramethyl-1,3,2-dioxoborolan-2-yl)-1H-indole. The invention compounds were evaluated in various biol. tests (some data given). The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Electric Literature of 936901-72-3

The Article related to imidazopyrazinamine preparation mtor kinase inhibitor treatment cancer, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Electric Literature of 936901-72-3

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On June 7, 2007, Mulvihill, Kristen Michelle; Castelhano, Arlindo L. published a patent.Category: pyrazines The title of the patent was Process for the preparation of substituted imidazo[1,5-a]pyrazines. And the patent contained the following:

The title compounds [I; X = Cl, Br, I; e.g., 3-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone] are prepared by the halogenation of 3-(8-chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone with either N-chloro-, N-bromo-, or N-iodosuccinimide (e.g., NBS) in a compatible solvent (e.g., DMF) at 0-60°. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Category: pyrazines

The Article related to bromochloroimidazopyrazinylcyclobutanone preparation, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyrazines

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On May 19, 2011, Epstein, David M.; Jin, Meizhong; Mulvihill, Mark J. published a patent.Category: pyrazines The title of the patent was Preparation of deuterated heteroaryl compounds as tyrosine kinase inhibitors. And the patent contained the following:

The title compounds with general formula I [wherein X = independently N or C-A; Y = independently N or C; Z = N, C-H, C-D, or N-A; W = independently N, N=O, or C-B; G = Ph or pyridyl, either optionally substituted by one or more D or halogen atoms; R = absent, D, optionally substituted C1-10 alkyl, C3-10cycloalkyl, etc.; where A = independently H, D, halogen, CF3, etc.; B = Me, Et, H, D, etc.; with the proviso that at least one of Y and Z is N or N-A, at least one of W is N or N=O, and any hydrogen atom can be replaced by a D atom and the compound or salt is present as a material comprising at least one D atom in an abundance of at least about 10 %] or pharmaceutically acceptable salts thereof were prepared as inhibitors of IGF-1R and IR. For example, compound II was prepared in a multi-step synthesis. Compounds I may inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and prevention of various diseases and conditions such as hyperproliferative disorders such as cancers. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Category: pyrazines

The Article related to preparation deuterated tyrosine kinase inhibitor quinoline imidazole triazine pyrazine, human treatment cancer hyperproliferative disorder antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Category: pyrazines

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem

On May 28, 2015, Laurent, Alain; Rose, Yannick published a patent.Recommanded Product: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone The title of the patent was Preparation of 8-aminoimidazo[3,4-a]pyrazine as Btk protein kinase inhibitors. And the patent contained the following:

The present invention relates to a novel family of protein kinase inhibitors, more specifically the present invention is directed to inhibitors of the members of the Tec and Src protein kinase families. The present invention also relates to processes for the preparation of these compounds [I; X = CH or N; R = H or each (un)substituted alkyl, heteroalkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl; W = OCH2R11 or CH2OR11; R1 = each (un)substituted aryl or heteroaryl; X1, X2 = H or halogen; m, m1 = an integer from O to 4] or pharmaceutically acceptable salts, solvates, solvates of salts, stereoisomers, tautomers, isotopes, prodrugs, complexes or biol. active metabolites thereof, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative, inflammatory, inflammatory and autoimmune diseases, disorders or conditions in which protein kinase activity is implicated. Thus, a solution of intermediate (II) (300 mg), intermediate (III) (397 mg), N,N-dimethylglycine (231 mg), cesium carbonate (1.1 g) and copper(I) iodide (141 mg) in 1,4-dioxane (1.5 mL) was heated in a pressure vessel at 110° overnight and then cooled to room temperature, followed by adding Et acetate, adsorbing the resulting mixture on silica gel, and purification by silica gel chromatog. to give 8-amino-1-(4-phenoxyphenyl)imidazo[3,4-a]pyrazine derivative (IV) as yellow solid. The experimental process involved the reaction of 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone(cas: 936901-72-3).Recommanded Product: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

The Article related to aminoimidazopyrazine aminophenoxyphenylimidazopyrazine preparation btk protein kinase inhibitor, proliferative disease inflammatory disease inflammatory autoimmune disease treatment aminoimidazopyrazine and other aspects.Recommanded Product: 3-(8-Chloroimidazo[1,5-a]pyrazin-3-yl)cyclobutanone

Referemce:
Pyrazine – Wikipedia,
Pyrazine | C4H4N2 – PubChem